Literature DB >> 25149048

More than 25 years of experience in managing pulmonary atresia with intact ventricular septum.

Adriaan W Schneider1, Nico A Blom2, Eline F Bruggemans1, Mark G Hazekamp3.   

Abstract

BACKGROUND: Management of pulmonary atresia with intact ventricular septum (PAIVS) is challenging and depends on the individual patient's morphologic characteristics. We evaluated outcomes of 25 years of experience in morphologically driven management of PAIVS.
METHODS: Between January 1985 and December 2011, 60 patients were treated for PAIVS. Patients were retrospectively categorized into mild (n=27), moderate (n=18), and severe (n=15) right ventricular (RV) hypoplasia subgroups based on morphologic characteristics at first presentation. Tricuspid valve (TV) annulus z score increases were analyzed in patients who underwent biventricular repair and in patients who underwent 1.5-ventricular repair. Median follow-up time was 9.8 years (range, 0-25 years). One patient was lost to follow-up.
RESULTS: Fifty-nine (98.3%) patients underwent operation. There were 7 early postprocedure deaths and 1 late death. Estimated overall survival was 86.5% at 10 years after initial admission for the total group, and 96.3%, 77.8%, and 79.4% for the subgroups, respectively. In the respective subgroups, biventricular repair was achieved in 24 (88.9%), 3 (16.7%), and 0 patients. In the patients who underwent biventricular repair, there was a significant increase of the TV annulus z score. At latest follow-up, mean New York Heart Association (NYHA) class was 1.3 for the total group and 1.1, 1.2, and 1.5 for the patients who underwent biventricular, 1.5-ventricular, and univentricular repair, respectively.
CONCLUSIONS: Our individualized management approach to PAIVS showed good early and long-term results. Early decision on the management goal, determined by individual morphologic characteristics at presentation, is of paramount importance. In specific patients, however, taking into account RV development at a later point in time may improve outcome.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25149048     DOI: 10.1016/j.athoracsur.2014.05.085

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Prenatal Echocardiographic Predictors of Postnatal Management Strategy in the Fetus with Right Ventricle Hypoplasia and Pulmonary Atresia or Stenosis.

Authors:  Li Cao; Zhiyun Tian; Jack Rychik
Journal:  Pediatr Cardiol       Date:  2017-08-02       Impact factor: 1.655

2.  Predictors of Mortality in Children with Pulmonary Atresia with Intact Ventricular Septum.

Authors:  Stephanie Grant; David Faraoni; James DiNardo; Kirsten Odegard
Journal:  Pediatr Cardiol       Date:  2017-09-04       Impact factor: 1.655

3.  Long-Term Outcomes After an Individualized Strategy in Patients with Pulmonary Atresia and Intact Ventricular Septum.

Authors:  Jun Muneuchi; Mamie Watanabe; Yuichiro Sugitani; Hirohito Doi; Takashi Furuta; Masaru Kobayashi; Hiroki Ezaki; Yoshie Ochiai
Journal:  Pediatr Cardiol       Date:  2021-09-24       Impact factor: 1.655

4.  Type I and II pulmonary atresia with intact ventricular septum in infants: a 10-year experience in initial surgery at one center.

Authors:  Hailong Song; Ziying Chen
Journal:  BMC Cardiovasc Disord       Date:  2022-03-17       Impact factor: 2.298

5.  Transthoracic Balloon Pulmonary Valvuloplasty for Treatment of Congenial Pulmonary Atresia Patients with Intact Ventricular Septum.

Authors:  Zhi-Qin Lin; Qiang Chen; Hua Cao; Liang-Wan Chen; Gui-Can Zhang; Dao-Zhong Chen; Qin-Min Wang; Han-Fan Qiu; Dong-Shan Liao; Feng Lin
Journal:  Med Sci Monit       Date:  2017-10-11

6.  Prenatal echocardiographic classification and prognostic evaluation strategy in fetal pulmonary atresia with intact ventricular septum.

Authors:  Lin Liu; Hongdan Wang; Cunying Cui; Yanan Li; Yuanyuan Liu; Ying Wang; Taibing Fan; Bangtian Peng
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.